Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate

Erich Durchschlag, Eleftherios P. Paschalis, Ruth Zoehrer, Paul Roschger, Peter Fratzl, Robert R. Recker, Roger Phipps, Klaus Klaushofer

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Long-term effects of risedronate on bone mineral maturity/crystallinity and collagen cross-link ratio in triple iliac crest biopsies of osteoporotic women were evaluated. In this double-blinded study, 3- and 5-year treatment with risedronate arrested the tissue aging encountered in untreated osteoporosis and in osteoporosis treated with other antiresorptives. This effect may be contributing to risedronate's antifracture efficacy. Introduction: Risedronate is widely used in the treatment of osteoporosis. It reduces bone turnover, increases BMD, and decreases fracture risk. To date, there are no data available on the long-term effects of risedronate on bone material properties in humans. Materials and Methods: Osteoporotic women enrolled in the VERT-NA trial received either risedronate (5 mg/day, orally) or placebo for up to 5 years. All subjects received calcium. They also received vitamin D supplementation if deficient at baseline. Triple iliac crest biopsies were collected from a subset of these subjects at baseline, 3 years, and 5 years. Mineral maturity/crystallinity and collagen cross-link ratio was measured in these biopsies using Fourier transform infrared imaging. Results: Patients that received placebo exhibited increased mineral maturity/crystallinity and collagen cross-link ratio after 3 and 5 years compared with baseline values. On the contrary, patients that received risedronate retained baseline values in both bone material indices throughout. A more spatially detailed analysis revealed that this was achieved mainly through beneficial effects on active bone-forming areas. Surprisingly, patients that received risedronate achieved premenopausal values at bone-forming areas in both indices after 5 years of treatment. Conclusion: Long-term treatment with risedronate affects bone material properties (mineral maturity/crystallinity and collagen cross-link ratio) and arrests the tissue aging apparent in untreated osteoporosis. These changes at the material level of the bone matrix may contribute to risedronate's rapid and sustained antifracture efficacy in osteoporotic patients.

Original languageEnglish
Pages (from-to)1581-1590
Number of pages10
JournalJournal of Bone and Mineral Research
Volume21
Issue number10
DOIs
StatePublished - Oct 2006

Fingerprint

Biopsy
Bone and Bones
Osteoporosis
Minerals
Collagen
Therapeutics
Placebos
Cancellous Bone
Risedronate Sodium
Bone Matrix
Bone Remodeling
Fourier Analysis
Vitamin D
Calcium

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. / Durchschlag, Erich; Paschalis, Eleftherios P.; Zoehrer, Ruth; Roschger, Paul; Fratzl, Peter; Recker, Robert R.; Phipps, Roger; Klaushofer, Klaus.

In: Journal of Bone and Mineral Research, Vol. 21, No. 10, 10.2006, p. 1581-1590.

Research output: Contribution to journalArticle

Durchschlag, E, Paschalis, EP, Zoehrer, R, Roschger, P, Fratzl, P, Recker, RR, Phipps, R & Klaushofer, K 2006, 'Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate', Journal of Bone and Mineral Research, vol. 21, no. 10, pp. 1581-1590. https://doi.org/10.1359/jbmr.060701
Durchschlag, Erich ; Paschalis, Eleftherios P. ; Zoehrer, Ruth ; Roschger, Paul ; Fratzl, Peter ; Recker, Robert R. ; Phipps, Roger ; Klaushofer, Klaus. / Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. In: Journal of Bone and Mineral Research. 2006 ; Vol. 21, No. 10. pp. 1581-1590.
@article{34caadcd80bd4327bf0eaadcf237165d,
title = "Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate",
abstract = "Long-term effects of risedronate on bone mineral maturity/crystallinity and collagen cross-link ratio in triple iliac crest biopsies of osteoporotic women were evaluated. In this double-blinded study, 3- and 5-year treatment with risedronate arrested the tissue aging encountered in untreated osteoporosis and in osteoporosis treated with other antiresorptives. This effect may be contributing to risedronate's antifracture efficacy. Introduction: Risedronate is widely used in the treatment of osteoporosis. It reduces bone turnover, increases BMD, and decreases fracture risk. To date, there are no data available on the long-term effects of risedronate on bone material properties in humans. Materials and Methods: Osteoporotic women enrolled in the VERT-NA trial received either risedronate (5 mg/day, orally) or placebo for up to 5 years. All subjects received calcium. They also received vitamin D supplementation if deficient at baseline. Triple iliac crest biopsies were collected from a subset of these subjects at baseline, 3 years, and 5 years. Mineral maturity/crystallinity and collagen cross-link ratio was measured in these biopsies using Fourier transform infrared imaging. Results: Patients that received placebo exhibited increased mineral maturity/crystallinity and collagen cross-link ratio after 3 and 5 years compared with baseline values. On the contrary, patients that received risedronate retained baseline values in both bone material indices throughout. A more spatially detailed analysis revealed that this was achieved mainly through beneficial effects on active bone-forming areas. Surprisingly, patients that received risedronate achieved premenopausal values at bone-forming areas in both indices after 5 years of treatment. Conclusion: Long-term treatment with risedronate affects bone material properties (mineral maturity/crystallinity and collagen cross-link ratio) and arrests the tissue aging apparent in untreated osteoporosis. These changes at the material level of the bone matrix may contribute to risedronate's rapid and sustained antifracture efficacy in osteoporotic patients.",
author = "Erich Durchschlag and Paschalis, {Eleftherios P.} and Ruth Zoehrer and Paul Roschger and Peter Fratzl and Recker, {Robert R.} and Roger Phipps and Klaus Klaushofer",
year = "2006",
month = "10",
doi = "10.1359/jbmr.060701",
language = "English",
volume = "21",
pages = "1581--1590",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate

AU - Durchschlag, Erich

AU - Paschalis, Eleftherios P.

AU - Zoehrer, Ruth

AU - Roschger, Paul

AU - Fratzl, Peter

AU - Recker, Robert R.

AU - Phipps, Roger

AU - Klaushofer, Klaus

PY - 2006/10

Y1 - 2006/10

N2 - Long-term effects of risedronate on bone mineral maturity/crystallinity and collagen cross-link ratio in triple iliac crest biopsies of osteoporotic women were evaluated. In this double-blinded study, 3- and 5-year treatment with risedronate arrested the tissue aging encountered in untreated osteoporosis and in osteoporosis treated with other antiresorptives. This effect may be contributing to risedronate's antifracture efficacy. Introduction: Risedronate is widely used in the treatment of osteoporosis. It reduces bone turnover, increases BMD, and decreases fracture risk. To date, there are no data available on the long-term effects of risedronate on bone material properties in humans. Materials and Methods: Osteoporotic women enrolled in the VERT-NA trial received either risedronate (5 mg/day, orally) or placebo for up to 5 years. All subjects received calcium. They also received vitamin D supplementation if deficient at baseline. Triple iliac crest biopsies were collected from a subset of these subjects at baseline, 3 years, and 5 years. Mineral maturity/crystallinity and collagen cross-link ratio was measured in these biopsies using Fourier transform infrared imaging. Results: Patients that received placebo exhibited increased mineral maturity/crystallinity and collagen cross-link ratio after 3 and 5 years compared with baseline values. On the contrary, patients that received risedronate retained baseline values in both bone material indices throughout. A more spatially detailed analysis revealed that this was achieved mainly through beneficial effects on active bone-forming areas. Surprisingly, patients that received risedronate achieved premenopausal values at bone-forming areas in both indices after 5 years of treatment. Conclusion: Long-term treatment with risedronate affects bone material properties (mineral maturity/crystallinity and collagen cross-link ratio) and arrests the tissue aging apparent in untreated osteoporosis. These changes at the material level of the bone matrix may contribute to risedronate's rapid and sustained antifracture efficacy in osteoporotic patients.

AB - Long-term effects of risedronate on bone mineral maturity/crystallinity and collagen cross-link ratio in triple iliac crest biopsies of osteoporotic women were evaluated. In this double-blinded study, 3- and 5-year treatment with risedronate arrested the tissue aging encountered in untreated osteoporosis and in osteoporosis treated with other antiresorptives. This effect may be contributing to risedronate's antifracture efficacy. Introduction: Risedronate is widely used in the treatment of osteoporosis. It reduces bone turnover, increases BMD, and decreases fracture risk. To date, there are no data available on the long-term effects of risedronate on bone material properties in humans. Materials and Methods: Osteoporotic women enrolled in the VERT-NA trial received either risedronate (5 mg/day, orally) or placebo for up to 5 years. All subjects received calcium. They also received vitamin D supplementation if deficient at baseline. Triple iliac crest biopsies were collected from a subset of these subjects at baseline, 3 years, and 5 years. Mineral maturity/crystallinity and collagen cross-link ratio was measured in these biopsies using Fourier transform infrared imaging. Results: Patients that received placebo exhibited increased mineral maturity/crystallinity and collagen cross-link ratio after 3 and 5 years compared with baseline values. On the contrary, patients that received risedronate retained baseline values in both bone material indices throughout. A more spatially detailed analysis revealed that this was achieved mainly through beneficial effects on active bone-forming areas. Surprisingly, patients that received risedronate achieved premenopausal values at bone-forming areas in both indices after 5 years of treatment. Conclusion: Long-term treatment with risedronate affects bone material properties (mineral maturity/crystallinity and collagen cross-link ratio) and arrests the tissue aging apparent in untreated osteoporosis. These changes at the material level of the bone matrix may contribute to risedronate's rapid and sustained antifracture efficacy in osteoporotic patients.

UR - http://www.scopus.com/inward/record.url?scp=33749259617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749259617&partnerID=8YFLogxK

U2 - 10.1359/jbmr.060701

DO - 10.1359/jbmr.060701

M3 - Article

C2 - 16995813

AN - SCOPUS:33749259617

VL - 21

SP - 1581

EP - 1590

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 10

ER -